Bedrock Therapeutics

Executive Summary

Bedrock Therapeutics is a privately held biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company is dedicated to developing novel gene therapies that target the genetic drivers of disease, with an initial focus on ocular disorders that impair vision and quality of life. By integrating computational biology with experimental approaches, Bedrock engineers advanced viral vectors and therapeutic modalities to achieve precise and durable genetic corrections. This platform has the potential to address a broad range of monogenic diseases, beginning with inherited retinal dystrophies where there is significant unmet medical need. As a preclinical-stage company, Bedrock is advancing its lead programs toward IND-enabling studies. The company has not yet disclosed specific pipeline candidates or financing rounds, but its innovative vector engineering approach could differentiate it from conventional gene therapies. Management's expertise in gene therapy and vector design positions the company to overcome key challenges such as immunogenicity and tissue targeting. If successful, Bedrock's therapies could provide life-altering benefits for patients with genetic vision loss and later expand into other therapeutic areas. The near-term outlook depends on securing additional funding and achieving preclinical milestones.

Upcoming Catalysts (preview)

• Q4 2026Lead program in vivo proof-of-concept data60% success
• Q1 2027Series A financing announcement70% success
• Q3 2027IND filing for lead candidate50% success